Monitor upcoming medical conference presentations (Q4 2026) for detailed data and any subsequent guidance updates. The results reinforce ILUVIEN's clinical value in chronic NIU-PS, potentially leading to increased prescription volume.
Price Chart
Executive Summary
ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the posterior segment (NIU-PS), meeting both co-primary endpoints with statistical significance. The results support the drug's safety and efficacy in a real-world setting, potentially boosting commercial uptake.
Key Facts
- SYNCHRONICITY trial met co-primary endpoints: mean change in BCVA (+3.6 letters, p<0.0077) and CST (-157.5 microns, p<0.0001) at 6 months.
- Safety profile consistent with prior ILUVIEN trials; 29% treatment-related TEAEs, most common ocular hypertension (6%) and cataract (5%).
- ILUVIEN already FDA-approved for DME (2014) and expanded for chronic NIU-PS (2025); this Phase 4 data adds real-world evidence.
- Detailed results to be presented at medical conferences in Q4 2026.
Financial Impact
Positive data could drive increased adoption of ILUVIEN for chronic NIU-PS, supporting revenue growth from the Rare Disease segment, but no revenue guidance provided.
Risk Factors
- Competition from other uveitis treatments; potential safety signals as real-world use expands.
- Commercial execution risk in building out the rare disease sales force.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $72.11 $77.91 | ▲ +8.04% | ▲ +7.23% | $71.97 (−0.19%) |
Sep 1, 2026 4w ago | Insider Cluster | $73.06 $71.46 | ▼ −2.19% | ▼ −1.23% | $71.97 (−1.49%) |
Aug 24, 2026 5w ago | 8-K | $74.17 $73.25 | ▼ −1.24% | ▼ −1.71% | $71.97 (−2.97%) |
Aug 13, 2026 7w ago | Insider Cluster | $74.77 $77.32 | ▲ +3.41% | ▲ +5.37% | $71.97 (−3.74%) |
Aug 7, 2026 8w ago | 8-K | $78.25 $76.54 | ▼ −2.19% | ▼ −2.58% | $71.97 (−8.03%) |
Jul 16, 2026 11w ago | Court Ruling | $81.92 $78.53 | ▼ −4.14% | ▼ −2.47% | $71.97 (−12.15%) |
Jul 13, 2026 11w ago | Press Release | $81.08 $79.20 | ▼ −2.32% | ▼ −1.53% | $71.97 (−11.24%) |
Jun 15, 2026 15w ago | Insider Cluster | $83.00 $82.94 | ▼ −0.07% | ▲ +2.16% | $71.97 (−13.29%) |
Jun 11, 2026 16w ago | Insider Cluster | $81.65 $80.52 | ▼ −1.38% | ▼ −1.82% | $71.97 (−11.86%) |
May 21, 2026 19w ago | 8-K | $82.72 $76.71 | ▼ −7.27% | ▼ −8.92% | $71.97 (−13.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access